US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gyre Therapeutics

7.42

+0.04000.54%

Post-market: 7.440.0200+0.27%18:08 EDT

Volume:1.05M

Turnover:7.80M

Market Cap:712.17M

PE:154.34

High:7.60

Open:7.38

Low:7.20

Close:7.38

Loading ...

Overview Company News Filings

Gyre Therapeutics 2.22M share Spot Secondary priced at $9.00

BRIEF-Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share

Gyre Therapeutics Inc - Prices Public Offering at $9.00 per Share

THOMSON REUTERS

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

THOMSON REUTERS

Gyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial Data

Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis

MT Newswires Live

BUZZ-Gyre Therapeutics tumbles after stock offering launch

BRIEF-Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock

Gyre Therapeutics Inc. Releases Results of Hydronidone Phase 3 Trial in CHB-Associated Liver Fibrosis

Gyre Therapeutics announces Hydronidone trial met primary endpoint

Gyre Therapeutics announces common stock offering, no amount given

Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in CHB-Associated Liver Fibrosis, Plans NDA Submission in China

Gyre Therapeutics Inc. Announces Launch of Public Offering for Common Stock

Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

THOMSON REUTERS

Gyre Therapeutics Inc - Proceeds to Advance Phase 2 Trial of F351 in Mash-Associated Liver Fibrosis

THOMSON REUTERS

Press Release: Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Gyre Therapeutics Inc. Granted Breakthrough Therapy Designation by China's NMPA for Hydronidone to Treat CHB-associated Liver Fibrosis

Gyre Therapeutics Inc - to Begin U.S. Phase 2 Trial for Mash-Associated Fibrosis in 2H2025

THOMSON REUTERS

Gyre Therapeutics Inc - Hydronidone Shows Favorable Safety Profile in Phase 3 Trial

THOMSON REUTERS

Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of Chb-Associated Liver Fibrosis in China

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":7.42,"timestamp":1751054400000,"preClose":7.38,"halted":0,"volume":1052009,"hourTrading":{"tag":"盘后","latestPrice":7.44,"preClose":7.42,"latestTime":"18:08 EDT","volume":397817,"amount":2951769.223362,"timestamp":1751062080619},"delay":0,"floatShares":25607700,"shares":95979800,"eps":0.048077,"marketStatus":"Market Closed","change":0.04,"latestTime":"06-27 16:00:00 EDT","open":7.38,"high":7.5973,"low":7.2,"amount":7800734.472550601,"amplitude":0.053835,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.048077,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":7.38,"postHourTrading":{"tag":"盘后","latestPrice":7.44,"preClose":7.42,"latestTime":"18:08 EDT","volume":397817,"amount":2951769.223362,"timestamp":1751062080619},"volumeRatio":5.623090823505809,"impliedVol":0.938,"impliedVolPercentile":0.7273},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":25607700,"roa":"5.18%","roe":"12.12%","lyrEps":0.142017,"volumeRatio":5.623090823505809,"shares":95979800,"dividePrice":0,"high":7.5973,"amplitude":0.053835,"preClose":7.38,"low":7.2,"week52Low":6.11,"pbRate":"10.45","psRate":"7.08","week52High":19,"institutionHeld":0.0832,"latestPrice":7.42,"eps":0.048077,"divideRate":0,"volume":1052009,"delay":0,"ttmEps":0.048077,"open":7.38,"prevYearClose":12.1,"prevWeekClose":8.07,"prevMonthClose":9.07,"prevQuarterClose":7.72,"fiveDayClose":8.07,"twentyDayClose":9.46,"sixtyDayClose":6.41},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537737903","title":"Gyre Therapeutics 2.22M share Spot Secondary priced at $9.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2537737903","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537737903?lang=en_us&edition=fundamental","pubTime":"2025-05-23 12:00","pubTimestamp":1747972834,"startTime":"0","endTime":"0","summary":"The deal priced below last closing price of $11.21. H.C. Wainwright is acting as sole book running manager for the offering. Published first on The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-2-22m-share-spot-secondary-priced-at-9-00-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-2-22m-share-spot-secondary-priced-at-9-00-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537979115","title":"BRIEF-Gyre Therapeutics Announces Pricing Of $20 Million Public Offering Of Common Stock At $9.00 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2537979115","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537979115?lang=en_us&edition=fundamental","pubTime":"2025-05-23 08:59","pubTimestamp":1747961964,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Announces Pricing Of $20 MillionPublic Offering Of Common Stock At $9.00 Per Share May 22 (Reuters) - Gyre Therapeutics Inc GYRE.O:GYRE THERAPEUTICS ANNOUNCES PRICING OF $20.0 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUA7QGQ8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537979693","title":"Gyre Therapeutics Inc - Prices Public Offering at $9.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2537979693","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537979693?lang=en_us&edition=fundamental","pubTime":"2025-05-23 08:57","pubTimestamp":1747961851,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUA7QGQ8D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537695979","title":"Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2537695979","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537695979?lang=en_us&edition=fundamental","pubTime":"2025-05-23 08:57","pubTimestamp":1747961851,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUA7QGQ8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537529978","title":"Gyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2537529978","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537529978?lang=en_us&edition=fundamental","pubTime":"2025-05-23 06:18","pubTimestamp":1747952280,"startTime":"0","endTime":"0","summary":"Shares of Gyre Therapeutics declined after the company announced an underwritten public stock offering, undercutting positive trial progress in China for its treatment for liver fibrosis.The stock fell 15% to $9.49 in after-hours trading. Shares have declined 17% in the past 12 months through Thursday's close.The biotechnology company said it plans to use the proceeds of the offering to advance its Phase 2 clinical trial of its Hydronidone compound to treat liver fibrosis in the U.S., as well as for research and development and other purposes.The company didn't disclose the size or share price of the offering. It expects to grant the underwriters a 30-day option to purchase additional shares at the public offering price.The offering lists Jefferies and H.C. Wainwright as its underwriters.The company also said Hydronidone met the primary endpoint in a Phase 3 trial to treat liver fibrosis in patients with chronic hepatitis B in China. The compound demonstrated a 53% regression in liver ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics Shares Fall as Stock Offering Overshadows Positive Trial Data","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537917920","title":"Gyre Therapeutics Meets Primary Endpoint for Compound to Treat Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2537917920","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537917920?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:36","pubTimestamp":1747949794,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  said its Hydronidone compound to treat liver fibrosis in patients with chronic hepatitis B met the primary endpoint in the phase 3 trial in China.The 52-week trial revealed that almost 53% of patients receiving Hydronidone achieved 1-stage regression in liver fibrosis versus placebo, Gyre said Thursday in a statement.The drug was well tolerated with no discontinuations due to adverse events, the company said.Gyre plans to present full trial results at a medical congress and file a new drug application with China's National Medical Products Administration in Q3.In a separate statement, Gyre announced a proposed underwritten public share offering with proceeds to advance its Phase 2 clinical trial of F351 in the US to treat liver fibrosis, among other things.Gyre shares fell 15% in after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COMP.USD.CC","COMP.USD.HKCC","GYRE","BK4139"],"gpt_icon":0},{"id":"2537927839","title":"BUZZ-Gyre Therapeutics tumbles after stock offering launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927839","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927839?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:37","pubTimestamp":1747946268,"startTime":"0","endTime":"0","summary":"BUZZ-Gyre Therapeutics tumbles after stock offering launch**  Shares of Gyre Therapeutics GYRE.O down 17.5% post-market to $9.25 as co seeks equity raise ** San Diego-based biotech commences stock offering; deal size not disclosed** It intends to use net offering proceeds to fund advancement of Phase II trial of F351 in metabolic dysfunction-associated steatohepatitis -associated liver fibrosis in the U.S., for R&D, and manufacturing among other uses** Jefferies lead bookrunner for offering** Co also says F351 met primary endpoint in pivotal Phase III evaluating efficacy and safety for treatment of fibrosis in patients with chronic hepatitis B in China** With ~93.8 mln shares outstanding, co has ~$1bln market cap** GYRE finished up 8.1% at $11.21 on Thurs, cutting YTD loss to ~7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nL6N3RU0U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","JEF","BK4559","BK4127","BK4139"],"gpt_icon":0},{"id":"2537922466","title":"BRIEF-Gyre Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2537922466","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537922466?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:27","pubTimestamp":1747945640,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Announces Proposed UnderwrittenPublic Offering Of Common StockGyre Therapeutics Inc GYRE.O:GYRE THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCKGYRE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA3WBNFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537161922","title":"Gyre Therapeutics Inc. Releases Results of Hydronidone Phase 3 Trial in CHB-Associated Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2537161922","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537161922?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:24","pubTimestamp":1747945483,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. has published a document detailing the Phase 3 trial results of Hydronidone  in treating liver fibrosis associated with chronic hepatitis B. The document includes information on the achievement of primary and secondary endpoints, a favorable safety profile, and future clinical and regulatory plans. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLbLGXbw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537392290","title":"Gyre Therapeutics announces Hydronidone trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2537392290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537392290?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:20","pubTimestamp":1747945230,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that its lead compound, Hydronidone, met the primary endpoint in a pivotal Phase 3 trial evaluating its efficacy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-hydronidone-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-hydronidone-trial-met-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537178922","title":"Gyre Therapeutics announces common stock offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2537178922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537178922?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:05","pubTimestamp":1747944341,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-common-stock-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-announces-common-stock-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537244489","title":"Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in CHB-Associated Liver Fibrosis, Plans NDA Submission in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2537244489","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537244489?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944162,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Announces Positive Phase 3 Trial Results for Hydronidone in CHB-Associated Liver Fibrosis, Plans NDA Submission in China. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL3kJSQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537244129","title":"Gyre Therapeutics Inc. Announces Launch of Public Offering for Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2537244129","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537244129?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944130,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc., a biotechnology company specializing in organ fibrosis, has announced the commencement of an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase additional shares at the public offering price, excluding underwriting discounts and commissions. The offering's completion and terms are dependent on market conditions, with no guarantees provided. The proceeds from this offering will be used to advance a Phase 2 clinical trial for F351 in the United States, focusing on MASH-associated liver fibrosis, as well as for research, development, manufacturing, and general corporate purposes. Jefferies is leading the offering as the book-running manager, with H.C. Wainwright & Co. acting as co-manager.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL5DMq4D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","BK4588","IE00B3QW5Z07.USD","NDAQ","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","LU2210150020.SGD","GYRE","LU2095319765.USD"],"gpt_icon":0},{"id":"2537924469","title":"Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924469?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA3WBNFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537924204","title":"Gyre Therapeutics Inc - Proceeds to Advance Phase 2 Trial of F351 in Mash-Associated Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924204?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA3WBNFZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537924402","title":"Press Release: Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924402","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924402?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:02","pubTimestamp":1747944120,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 22, 2025  -- Gyre Therapeutics  , an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Gyre is expected to grant the underwriters of the offering an option for a period of 30 days to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock to be sold in the offering are being offered by Gyre.Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537474924","title":"Gyre Therapeutics Inc. Granted Breakthrough Therapy Designation by China's NMPA for Hydronidone to Treat CHB-associated Liver Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2537474924","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537474924?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:01","pubTimestamp":1747944097,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc. Granted Breakthrough Therapy Designation by China's NMPA for Hydronidone to Treat CHB-associated Liver Fibrosis. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLbxcVvK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","NDAQ","BK4112","BK4588","IE00BGHQF748.EUR","BK4585","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2537784924","title":"Gyre Therapeutics Inc - to Begin U.S. Phase 2 Trial for Mash-Associated Fibrosis in 2H2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2537784924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537784924?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:01","pubTimestamp":1747944060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA4WSMW5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2537416924","title":"Gyre Therapeutics Inc - Hydronidone Shows Favorable Safety Profile in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2537416924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537416924?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:01","pubTimestamp":1747944060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA4WSMW5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2537241719","title":"Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of Chb-Associated Liver Fibrosis in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2537241719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537241719?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:01","pubTimestamp":1747944060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA4WSMW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-09","symbol":"GYRE","fiscalQuarterEnding":"2025/03","expectedEps":0.03,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":0},{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01},{"date":"2025-02-18","symbol":"GYRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739869200000,"name":null,"time":"Pre-Market","dateTimestamp":1739854800000,"actualEps":null},{"market":"US","date":"2024-11-13","symbol":"GYRE","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":0.02},{"market":"US","date":"2024-08-13","symbol":"GYRE","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2025-06-27","current":92.269436,"percent":0.887372,"low":-11548.718266,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"high":139.727206,"avg":-1155.549062,"sd":3094.591864,"marketCap":669045678},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789},{"date":"2025-04-25","current":70.645053,"twenty":-30.585076,"median":-12.780906,"eighty":-10.377285,"marketCap":853745471},{"date":"2025-05-02","current":72.449806,"twenty":-30.310846,"median":-12.626921,"eighty":-10.338636,"marketCap":875555902},{"date":"2025-05-09","current":73.535777,"twenty":-30.136978,"median":-12.473999,"eighty":-10.164715,"marketCap":888679866},{"date":"2025-05-16","current":132.923099,"twenty":-29.947887,"median":-12.417259,"eighty":-9.938068,"marketCap":963825388},{"date":"2025-05-23","current":136.20365,"twenty":-29.754799,"median":-12.327984,"eighty":-9.652614,"marketCap":987612669},{"date":"2025-05-30","current":117.840031,"twenty":-29.349619,"median":-12.308068,"eighty":-9.440044,"marketCap":854458067},{"date":"2025-06-06","current":99.64599,"twenty":-28.753768,"median":-12.251767,"eighty":50.257139,"marketCap":722533070},{"date":"2025-06-13","current":100.896253,"twenty":-28.630129,"median":-12.168656,"eighty":56.159719,"marketCap":731598729},{"date":"2025-06-20","current":104.146938,"twenty":-27.795567,"median":-12.087508,"eighty":59.335648,"marketCap":755169444},{"date":"2025-06-27","current":92.269436,"twenty":-26.976012,"median":-11.969641,"eighty":62.92987,"marketCap":669045678}],"updateTime":1751107694703}}}